Drug · CHEMBL457
GEMFIBROZIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. GEMFIBROZIL. Drugs and targets, record CHEMBL457. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL457
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 4 of its 10 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PPARA | Peroxisome proliferator-activated receptor alpha | Peroxisome proliferator-activated receptor alpha agonist | AGONIST | https://conductscience.org/library/genes/5465 |
Source ChEMBL
Diseases10
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
Source Open Targets
Trials34
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT05959447 | Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant | Phase 1 | 45 | 2025-03-26 | gemfibrozil | Its name | ClinicalTrials.gov |
| NCT01836198 | The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream | Phase 1 | 30 | 2019-03-08 | gemfibrozil | Its name | ClinicalTrials.gov |
| NCT01876810 | Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction | Phase 2 | 28 | 2017-04-20 | gemfibrozil | Its name | ClinicalTrials.gov |
| NCT01736254 | A Study of Evacetrapib in Healthy Participants | Phase 1 | 24 | 2018-10-03 | gemfibrozil | Its name | ClinicalTrials.gov |
| NCT01301742 | Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers | Phase 1 | 18 | 2014-06-18 | gemfibrozil | Its name | ClinicalTrials.gov |
| NCT02638597 | Gemfibrozil for Nicotine Smoking Cessation | Phase 2 | 16 | 2019-02-01 | gemfibrozil | Its name | ClinicalTrials.gov |
| NCT00474201 | Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil | 15 | 2012-04-09 | gemfibrozil | Its name | ClinicalTrials.gov | |
| NCT03539432 | Exploration of Gemfibrozil as a Treatment for AUD | Phase 2 | 3 | 2021-10-18 | gemfibrozil | Its name | ClinicalTrials.gov |
| NCT00283335 | The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol | Phase 3 | 2,531 | gemfibrozil | Its name | ClinicalTrials.gov | |
| NCT03723395 | A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib | Phase 1 | 116 | gemfibrozil | Its name | ClinicalTrials.gov |
1 to 10 of 34
See all 34 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Gemfibrozil/Placebo vs Placebo/Gemfibrozil: deaths from any cause | 0 of 14 | 0 of 13 | 27 | NCT01876810 | Trial comparisons |
| Gemfibrozil/Placebo vs Placebo/Gemfibrozil: serious adverse events | 0 of 14 | 0 of 13 | 27 | NCT01876810 | Trial comparisons |
| Gemfibrozil vs Waitlist: serious adverse events | 0 of 8 | 0 of 8 | 16 | NCT02638597 | Trial comparisons |
| Gemfibrozil vs Placebo: deaths from any cause | 0 of 2 | 0 of 1 | 3 | NCT03539432 | Trial comparisons |
| Gemfibrozil vs Placebo: serious adverse events | 0 of 2 | 0 of 1 | 3 | NCT03539432 | Trial comparisons |
Papers from its trials12
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Paired Associate Learning | 1 | 0 | ConductCognition |
| Selective Reminding Task | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL457
GET https://conductscience.org/api/drugs/v1/CHEMBL457/trials?page=2